作者: N Harbeck , M Untch , L Pache , W Eiermann
DOI: 10.1038/BJC.1994.103
关键词: Oncology 、 Pathology 、 Breast cancer 、 Tamoxifen 、 Carcinoma 、 Cyclophosphamide 、 Mammary gland 、 Median follow-up 、 Medicine 、 Bone marrow 、 Survival analysis 、 Internal medicine
摘要: … -positive patients have since relapsed, but only 9/62 (15%) tumour cell-negative patients. The median interval between tumour cell detection and relapse was 11.4 months. No …